London: AbbVie agreed to pay up to USD 2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on Thursday, marking an early-stage push by the drugmaker on next-generation bispecific therapies.

Bispecific antibodies, a class of cancer medicines that bind two targets at once, have drawn increased interest from big drugmakers including Bristol Myers Squibb, Pfizer and Merck.

In January, AbbVie paid RemeGen $650 million upfront for rights outside China to a bispecific medicine targeting solid tumors.

Disco will receive $40 million upfront and up to $2.5 billion in milestone payments as part of the deal to develop so-called AND-gated bispecific therapeutics for solid tumors. It will also be eligible for tiered royalties on worldwide net sales.

The approach is designed to recognize cancer cells only when two target proteins are present simultaneously, potentially reducing damage to healthy tissue.

Disco CEO Mark Manfredi said his company will be responsible for the research and discovery. AbbVie will have the right to exclusively license selected programs for further development.

"(AbbVie) brings a wealth of information, a wealth of experience in target biology, so we will learn from them and we will work with them on how to select targets," said Manfredi.

The deal is at a very early stage. Disco did not disclose how many programs could be covered or when any could enter clinical development, and AbbVie's license option applies only after Disco completes specified research.

Disco has been developing AND-gated therapies for small-cell lung and colorectal cancer, and Manfredi said the company will select a development candidate in the second half of next year.

Other recent bispecific deals include Bristol Myers Squibb's up to $11.1 billion partnership with BioNTech, Takeda's multibillion-dollar deal with China's Innovent and UCB's $2.2 billion acquisition of Candid Therapeutics.

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .